NewLimit closed a $45 million financing round that included investment from Lilly Ventures and S32, positioning the anti‑aging startup to advance preclinical and early clinical programs. The company, co‑founded by serial entrepreneurs and backed by notable investors, aims to commercialize therapeutics targeting aging biology. NewLimit will use proceeds to accelerate target validation and translational work that underpins its longevity claims. Lilly’s participation signals big‑pharma interest in therapeutic programs addressing aging pathways and potential downstream partnerships or licensing conversations. Investors and researchers will watch for preclinical benchmarks and translational milestones that could de‑risk the company’s pipeline and shape the competitive landscape in geroscience therapeutics.